Month: January 2019
January 30, 2019
Tafamidis accepted for FDA Review in 2019
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)
Read More
- Categories
- Archives
- November 2024 (1)
- October 2024 (1)
- March 2024 (1)
- February 2024 (1)
- December 2023 (1)
- November 2023 (1)
- October 2023 (1)
- May 2023 (1)
- March 2023 (2)
- February 2023 (1)
- October 2022 (3)
- July 2022 (1)
- June 2022 (1)
- April 2022 (1)
- February 2022 (2)
- November 2021 (2)
- September 2021 (1)
- June 2021 (1)
- May 2021 (1)
- March 2021 (1)
- February 2021 (1)
- January 2021 (2)
- December 2020 (1)
- November 2020 (2)
- October 2020 (1)
- September 2020 (1)
- August 2020 (1)
- July 2020 (1)
- February 2020 (2)
- January 2020 (2)
- December 2019 (1)
- November 2019 (3)
- October 2019 (1)
- September 2019 (3)
- August 2019 (1)
- June 2019 (1)
- May 2019 (2)
- March 2019 (2)
- February 2019 (1)
- January 2019 (1)
- December 2018 (3)
- October 2018 (2)
- September 2018 (1)
- August 2018 (2)
- July 2018 (2)
- April 2018 (3)
- March 2018 (2)
- February 2018 (3)
- January 2018 (2)
- December 2017 (4)
- November 2017 (2)
- October 2017 (1)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- April 2017 (1)
- February 2017 (1)
- December 2016 (2)
- October 2016 (2)
- September 2016 (1)
- July 2016 (3)
- June 2016 (4)
- May 2016 (1)
- April 2016 (2)
- March 2016 (1)
- February 2016 (2)
- December 2015 (1)
- November 2015 (2)
- October 2015 (1)
- September 2015 (1) More
